A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis

Inhibition of IL-4/IL-13 signaling has dramatically improved the treatment of atopic dermatitis (AD). However, in many patients, clinical responses are slow to develop and remain modest. Indeed, some symptoms of AD are dependent on IL-31, which is only partially reduced by IL-4/IL-13 inhibition. Thu...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Julia Tietz, Tea Gunde, Stefan Warmuth, Christopher Weinert, Matthias Brock, Alexandre Simonin, Christian Hess, Maria Johansson, Fabio Spiga, Simone Muntwiler, Belinda Wickihalder, Dana Mahler, Dania Diem, Julia Zeberer, Robin Heiz, Naomi Flückiger, Noriko Shiraishi, Yoshihide Miyake, Nobuaki Takahashi, Markus Fehrholz, Marta Bertolini, Peter Lichtlen, David Urech, Daniel Snell
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2024-03-01
Rangatū:	JID Innovations
Ngā marau:	Atopic dermatitis Cytokines Inflammatory skin diseases Pruritus
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2667026724000043
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!